Literature DB >> 18584574

The effects of levetiracetam on alcohol consumption in alcohol-dependent subjects: an open label study.

Ofra Sarid-Segal1, Joanna Piechniczek-Buczek, Clifford Knapp, Maryam Afshar, Eric Devine, Laurie Sickles, Emma Uwodukunda, Courtney Richambault, Jillian Koplow, Domenic Ciraulo.   

Abstract

The aim of this open-label pilot study was to assess the efficacy and safety of the novel anticonvulsant agent, levetiracetam, for the treatment of alcohol dependence. A maximal dose of 2000 mg was administered daily for 10 weeks to alcohol dependent subjects (n = 20). Mean reported ethanol intake declined significantly from 5.3 to 1.7 standard drinks per day. Levetiracetam was well tolerated by most subjects.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18584574      PMCID： PMC5377927          DOI： 10.1080/00952990802082180

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN： 0095-2990            Impact factor:   3.829


  23 in total

1.  Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.

Authors:  Michael Krebs; Karolina Leopold; Christoph Richter; Thorsten Kienast; Axel Hinzpeter; Andreas Heinz; Martin Schaefer
Journal:  J Clin Psychopharmacol       Date:  2006-06       Impact factor: 3.153

2.  A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.

Authors:  T I Mueller; R L Stout; S Rudden; R A Brown; A Gordon; D A Solomon; P R Recupero
Journal:  Alcohol Clin Exp Res       Date:  1997-02       Impact factor: 3.455

3.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

4.  Initial evidence for the reliability and validity of a "Lite" version of the Addiction Severity Index.

Authors:  John S Cacciola; Arthur I Alterman; A Thomas McLellan; Yi-Ting Lin; Kevin G Lynch
Journal:  Drug Alcohol Depend       Date:  2006-10-11       Impact factor: 4.492

5.  Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention.

Authors:  Lance P Longo; Todd Campbell; Sandra Hubatch
Journal:  J Addict Dis       Date:  2002

6.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

7.  The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate.

Authors:  Bettina Gomer; Kathrin Wagner; Lars Frings; Josef Saar; Astrid Carius; Markus Härle; Bernhard J Steinhoff; Andreas Schulze-Bonhage
Journal:  Epilepsy Behav       Date:  2007-04-03       Impact factor: 2.937

8.  An open-label study of levetiracetam for the treatment of social anxiety disorder.

Authors:  Naomi M Simon; John J Worthington; Alicia C Doyle; Elizabeth A Hoge; Gustavo Kinrys; Diana Fischmann; Nathaniel Link; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2004-09       Impact factor: 4.384

Review 9.  Clinical pharmacokinetics of levetiracetam.

Authors:  Philip N Patsalos
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Levetiracetam as adjunctive therapy for refractory anxiety disorders.

Authors:  Gustavo Kinrys; John J Worthington; Lisa Wygant; Fernanda Nery; Hannah Reese; Mark H Pollack
Journal:  J Clin Psychiatry       Date:  2007-07       Impact factor: 4.384
View more
  10 in total

Review 1.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 2.  Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders.

Authors:  Christopher J Hammond; Mark J Niciu; Shannon Drew; Albert J Arias
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

3.  Determining the polymer threshold amount for achieving robust drug release from HPMC and HPC matrix tablets containing a high-dose BCS class I model drug: in vitro and in vivo studies.

Authors:  Uroš Klančar; Saša Baumgartner; Igor Legen; Polona Smrdel; Nataša Jeraj Kampuš; Dejan Krajcar; Boštjan Markun; Klemen Kočevar
Journal:  AAPS PharmSciTech       Date:  2014-10-18       Impact factor: 3.246

4.  A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Authors:  Joanne B Fertig; Megan L Ryan; Daniel E Falk; Raye Z Litten; Margaret E Mattson; Janet Ransom; William J Rickman; Charles Scott; Domenic Ciraulo; Alan I Green; Nassima A Tiouririne; Bankole Johnson; Helen Pettinati; Eric C Strain; Eric Devine; Mary F Brunette; Kyle Kampman; David A Tompkins; Robert Stout
Journal:  Alcohol Clin Exp Res       Date:  2012-02-10       Impact factor: 3.455

5.  Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.

Authors:  Eric W Fish; Abigail E Agoglia; Michael C Krouse; R Grant Muller; J Elliott Robinson; C J Malanga
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

Review 6.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

7.  Levetiracetam has opposite effects on alcohol- and cocaine-related behaviors in C57BL/6J mice.

Authors:  J Elliott Robinson; Meng Chen; Alice M Stamatakis; Michael C Krouse; Elaina C Howard; Sara Faccidomo; Clyde W Hodge; Eric W Fish; C J Malanga
Journal:  Neuropsychopharmacology       Date:  2013-01-25       Impact factor: 7.853

8.  Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.

Authors:  Clifford M Knapp; Domenic A Ciraulo; Ofra Sarid-Segal; Mark A Richardson; Eric Devine; Chris C Streeter; Marlene Oscar-Berman; Caitlin Surprise; Laurie Colaneri; Meghan Putnam; Megan Waters; Courtney Richambault
Journal:  J Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.153

Review 9.  Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment.

Authors:  Robin C Wackernah; Matthew J Minnick; Peter Clapp
Journal:  Subst Abuse Rehabil       Date:  2014-01-23

10.  Postseizure aphasia in Wernicke's encephalopathy: a case report and review of literature.

Authors:  Sandhya Devaraj; Sara A Muralles; Chandler E Gill; Edwin Meresh
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-08       Impact factor: 2.570
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.